The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

Lupus nephritis is a serious complication of lupus that is caused by inflammation of the kidneys. It affects up to 60% of people with lupus and usually occurs within 5 years of diagnosis. If left ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treated with calcineurin inhibitors vs ...

Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...

NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

This transcript has been edited for clarity. Matthew A. Sparks, MD: I'm Dr Matthew Sparks, and welcome to Medscape's InDiscussion podcast series on chronic kidney disease. Today we'll be discussing ...

CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 22, 2026, Health Canada has approved Gazyva® (obinutuzumab) for ...

Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse effects, but the ideal timing is uncertain. This study followed 136 lupus ...

The trial met its primary endpoint showing a significant improvement in complete renal response with obinutuzumab with standard therapy vs standard therapy alone after 76 weeks. Positive topline ...

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.

Investigators studied expression of type I interferons, key pathogenic drivers in systemic lupus erythematosus and lupus nephritis.